Estramustine-Binding Protein (EMBP) in Renal Cell Carcinoma Immunohistochemistry, Immunoscintigraphy and in Vitro Estramustine Effects

References

• Rosenberg S. A., Lotze M. T., Muul L. M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92
   PubMed Web of Science ®Google Scholar
• West W. H., Kurt M. D., Tauer W., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990; 335: 1509–12
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Swanson D. A., Trindade A., et al. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983; 43: 940–7
   PubMed Web of Science ®Google Scholar
• Hudes G. R., Ozols R. F., Schilder R. J. Genitourinary cancer. Cancer chemotherapy and biological response modifiers, H.M. Pinedo, D. L. Logo, B. A. Chabner. Elsevier Biomedical Press, Amsterdam 1991; 12: 509–48
   Google Scholar
• Buzaid A. C., Todd M. B. Therapeutic options in renal cell carcinoma. Semin Oncol 1989; 16: 12–9
   PubMed Web of Science ®Google Scholar
• Krown S. E. Therapeutic options in renal cell carcinoma. Semin Oncol 1985; 5: 13–7
   Google Scholar
• Jönsson G., Hogberg B. Treatment of advanced prostatic carcinoma with Estracyt. A preliminary report. Scand J Urol Nephrol 1971; 5: 103–10
   PubMedGoogle Scholar
• Khoury S. Hormone-resistant prostatic cancer: Management. Prostate cancer, S. Khoury, C. Chatelain, G. Murphy, L. Denis. Paris, FIIS, Urology 1990; 526–30
   Google Scholar
• Benson R. C., Gill G. M. Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 1986; 9: 341–351
   PubMed Web of Science ®Google Scholar
• Gunnarsson P. O., Plym-Forshell G., Fritjofsson Å, Norlén B. J. Plasma concentrations of estramustine and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt). Scand J Urol Nephrol 1981; 15: 201–6
   PubMed Web of Science ®Google Scholar
• Norlén B. J., Andersson S-B, Björk P., Gunnarsson P. O., Fritjofsson Å. Uptake of estramustine phosphate (Estracyt) metabolites in prostatic cancer. J Urol 1988; 140: 1058–62
   PubMedGoogle Scholar
• Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DDU145 and PC-3. Prostate 1984; 5: 93–100
   PubMed Web of Science ®Google Scholar
• Stearns M. E., Tew K. D. Antimicrotubule effects of estramustine an antiprostatic tumor drug. Cancer Res 1985; 45: 3891–7
   PubMed Web of Science ®Google Scholar
• Forsgrgn B., Björk P., Carlström K., Gustafsson J-Å, Högberg B. Purification and distribution of a major protein in the rat prostate that binds estramustine: a nitrogen mustard derivative of estradiol-17(B). Proc Natl Acas Sci USA 1979; 76: 3149–53
   PubMedGoogle Scholar
• Björk P., Forsgren B., Gustafsson J-Å, Pousette Å, Högberg B. Partial characterization and ‘quantitation’ of a human prostatic estramustine-binding protein. Cancer Res 1982; 42: 1935–42
   PubMed Web of Science ®Google Scholar
• Eklöv S., Larson A., Björk P., Nilsson S. The expression of estramustine-binding protein in the human prostatic cancer cell line DU-145 is not androgen dependent. Scand J Urol Nephrol 1992; 26: 119–25
   PubMed Web of Science ®Google Scholar
• de la Torre M., Eklöv S., Haggman M., Björk P., Busch C., Nilsson S. Elevated expression of estramustine-binding protein (EMBP) in prostatic intraepithelial neoplasia compared with malignant and benign prostatic epithelia. Prostate 1994; 25: 125–31
   PubMedGoogle Scholar
• Bergh J., Westlin J-E, Brodin O., Björk P., Nilsson S. Expression of estramustine-binding associated protein in human lung cancer cell lines. Cancer Res 1988; 48: 4615–9
   PubMedGoogle Scholar
• Björk P., Borg Å, Fernö M, Nilsson S. Expression and partial characterization of estramustine-binding protein (EMBP) in human breast cancer and malignant melanoma. Anticancer Res 1991; 11: 1173–82
   PubMedGoogle Scholar
• Eklöv S., Essand M., Carlsson J., Nilsson S. Radiation sensitization by estramustine. Studies on cultured human prostatic cancer cells. Prostate 1992; 21: 287–95
   PubMedGoogle Scholar
• Eklöv S., Nilsson S., Larson A., Björk P., Hartley-Asp B. Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate 1992; 20: 43–50
   PubMed Web of Science ®Google Scholar
• Larsson R., Nygren P. A rapid fluorimetric method for semi-automated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 1989; 9: 1111–20
   PubMed Web of Science ®Google Scholar
• Sternberger L. A. Immunocytochemistry. 2nd ed. John Wiley and Sons, New York 1979; pp: 104–69
   Google Scholar
• Greenwood F. C., Hunter W. M., Glover J. S. The preparation of 1311 labelled human growth hormone of high specific activity. Biochem J 1963; 89: 114–23
   PubMed Web of Science ®Google Scholar